Significant Impact of IL-6 -174G/C but Inverse Relation with -634 C/G Polymorphism in Patients with Non-Small Cell Lung Cancer in Kashmiri Population

References

• Aggarwal BB, Shishodia S, Sandur SK, et al. (2006). Inflammation and cancer: how hot is the link? Biochem Pharmacol, 72, 1605–21
   PubMed Web of Science ®Google Scholar
• Apostolou P, Tsantsaridou A, Papasotiriou I, et al. (2011). Bacterial and fungal microflora in surgically removed lung cancer samples. J Cardiothor Surg, 6, 137
   PubMed Web of Science ®Google Scholar
• Bennermo M, Held C, Stemme S, et al. (2004). Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem, 50, 2136–40
   PubMed Web of Science ®Google Scholar
• Berek JS, Chung C, Kaldi K, et al. (1991). Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol, 164, 1038–42; discussion 1042–3
   PubMed Web of Science ®Google Scholar
• Brenner DR, Boffetta P, Duell EJ, et al. (2012). Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol, 176, 573–85
   PubMed Web of Science ®Google Scholar
• Campa D, Zienolddiny S, Maggini V, et al. (2004). Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis, 25, 229–35
   PubMed Web of Science ®Google Scholar
• Chang SH, Mirabolfathinejad SG, Katta H, et al. (2014). T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci USA, 111, 5664–9
   PubMed Web of Science ®Google Scholar
• Chen Z, Malhotra PS, Thomas GR, et al. (1999). Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res, 5, 1369–79
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. (2002). Inflammation and cancer. Nature, 420, 860–7
   PubMed Web of Science ®Google Scholar
• Cummins J, Tangney M. (2013). Bacteria and tumours: causative agents or opportunistic inhabitants? Infect Agent Cancer, 8, 11
   PubMedGoogle Scholar
• Dela Cruz CS, Tanoue LT, Matthay RA. (2011). Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med, 32, 605–44
   PubMed Web of Science ®Google Scholar
• Duan Z, Feller AJ, Penson RT, et al. (1999). Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res, 5, 3445–53
   PubMed Web of Science ®Google Scholar
• Duan Z, Lamendola DE, Penson RT, et al. (2002). Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine, 17, 234–42
   PubMed Web of Science ®Google Scholar
• Fernandez-Real JM, Broch M, Vendrell J, et al. (2000). Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab, 85, 1334–9
   PubMed Web of Science ®Google Scholar
• Ganesh B, Sushama S, Monika S, Suvarna P. (2011). A case-control study of risk factors for lung cancer in Mumbai, India. Asian Pac J Cancer Prev, 12, 357–62
   PubMed Web of Science ®Google Scholar
• Guo Y, Xu F, Lu T, et al. (2012). Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev, 38, 904–10
   PubMed Web of Science ®Google Scholar
• Haddy N, Sass C, Maumus S, et al. (2005). Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. Eur J Hum Genet, 13, 109–17
   PubMed Web of Science ®Google Scholar
• He JQ, Foreman MG, Shumansky K, et al. (2009). Associations of IL6 polymorphisms with lung function decline and COPD. Thorax, 64, 698–704
   PubMed Web of Science ®Google Scholar
• Hong DS, Angelo LS, Kurzrock R. (2007). Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer, 110, 1911–28
   PubMed Web of Science ®Google Scholar
• Jackson LA, Wang SP, Nazar-Stewart V, et al. (2000). Association of Chlamydia pneumoniae immunoglobulin A seropositivity and risk of lung cancer. Cancer Epidemiol Biomarkers Prev, 9, 1263–6
   PubMed Web of Science ®Google Scholar
• Ju R, Wu D, Guo L, et al. (2012). Inhibition of pro-inflammatory cytokines in tumour associated macrophages is a potential anti-cancer mechanism of carboxyamidotriazole. Eur J Cancer, 48, 1085–95
   PubMed Web of Science ®Google Scholar
• Karin M. (2006). Nuclear factor-kappaB in cancer development and progression. Nature, 441, 431–6
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. (2005). NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 5, 749–59
   PubMed Web of Science ®Google Scholar
• Kitamura A, Hasegawa G, Obayashi H, et al. (2002). Interleukin-6 polymorphism (-634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med, 19, 1000–5
   PubMed Web of Science ®Google Scholar
• Lim CS, Zheng S, Kim YS, et al. (2002). The –174 G to C polymorphism of interleukin-6 gene is very rare in koreans. Cytokine, 19, 52–4
   PubMed Web of Science ®Google Scholar
• Lim WY, Chen Y, Ali SM, et al. (2011). Polymorphisms in inflammatory pathway genes, host factors and lung cancer risk in Chinese female never-smokers. Carcinogenesis, 32, 522–9
   PubMed Web of Science ®Google Scholar
• Lu C, Sheehan C, Rak JW, et al. (1996). Endogenous interleukin 6 can function as an in vivo growth- stimulatory factor for advanced-stage human melanoma cells. Clin Cancer Res, 2, 1417–25
   PubMed Web of Science ®Google Scholar
• Mantovani A. (2005). Cancer: inflammation by remote control. Nature, 435, 752–3
   PubMed Web of Science ®Google Scholar
• Margaglione M, Bossone A, Cappucci G, et al. (2001). The effect of the interleukin-6 c/g-174 polymorphism and circulating interleukin-6 on fibrinogen plasma levels. Haematologica, 86, 199–204
   PubMedGoogle Scholar
• Mouawad R, Benhammouda A, Rixe O, et al. (1996). Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res, 2, 1405–9
   PubMed Web of Science ®Google Scholar
• Nakajima T, Ota N, Yoshida H, et al. (1999). Allelic variants in the interleukin-6 gene and essential hypertension in Japanese women. Genes Immun, 1, 115–9
   PubMed Web of Science ®Google Scholar
• Nandakumar A. (2001). Consolidated report of the population based cancer registries, incidence & distribution of cancer, 1990–1996. New Delhi: Indian Council of Medical Research
   Google Scholar
• Oberbach A, Lehmann S, Kirsch K, et al. (2008). Long-term exercise training decreases interleukin-6 (IL-6) serum levels in subjects with impaired glucose tolerance: effect of the -174G/C variant in IL-6 gene. Eur J Endocrinol, 159, 129–36
   PubMed Web of Science ®Google Scholar
• Oka M, Yamamoto K, Takahashi M, et al. (1996). Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res, 56, 2776–80
   PubMed Web of Science ®Google Scholar
• Pandith AA, Siddiqi MA. (2012). Burden of cancers in the valley of Kashmir: 5 year epidemiological study reveals a different scenario. Tumour Biol, 33, 1629–37
   PubMed Web of Science ®Google Scholar
• Peng WJ, He Q, Yang JX, et al. (2012). Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk. Mol Biol Rep, 39, 5187–94
   PubMed Web of Science ®Google Scholar
• Pu YS, Hour TC, Chuang SE, et al. (2004). Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate, 60, 120–9
   PubMed Web of Science ®Google Scholar
• Rauramaa R, Vaisanen SB, Luong LA, et al. (2000). Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol, 20, 2657–62
   PubMed Web of Science ®Google Scholar
• Rogers MB. (2011). Mycoplasma and cancer: in search of the link. Oncotarget, 2, 271–3
   PubMedGoogle Scholar
• Ryu JH, Kim SJ. (2012). Interleukin-6 -634 C/G and -174 G/C polymorphisms in Korean patients undergoing hemodialysis. Kor J Intern Med, 27, 327–37
   PubMed Web of Science ®Google Scholar
• Sanders J, Hawe E, Brull DJ, et al. (2009). Higher IL-6 levels but not IL6 -174G>C or -572G>C genotype are associated with post-operative complication following coronary artery bypass graft (CABG) surgery. Atherosclerosis, 204, 196–201
   PubMed Web of Science ®Google Scholar
• Scambia G, Testa U, Benedetti Panici P, et al. (1995). Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer, 71, 354–6
   PubMed Web of Science ®Google Scholar
• Schwabe RF, Jobin C. (2013). The microbiome and cancer. Nat Rev Cancer, 13, 800–12
   PubMed Web of Science ®Google Scholar
• Seow A, Ng DP, Choo S, et al. (2006). Joint effect of asthma/atopy and an IL-6 gene polymorphism on lung cancer risk among lifetime non-smoking Chinese women. Carcinogenesis, 27, 1240–4
   PubMed Web of Science ®Google Scholar
• Shafia S, Afroze D, Sofi FA, et al. (2014). Rheumatoid arthritis and genetic variations in cytokine genes: a population-based study in Kashmir Valley. Immunol Invest, 43, 349–59
   PubMed Web of Science ®Google Scholar
• Shariat SF, Andrews B, Kattan MW, et al. (2001). Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology, 58, 1008–15
   PubMed Web of Science ®Google Scholar
• Srisuma S, Biswal SS, Mitzner WA, et al. (2003). Identification of genes promoting angiogenesis in mouse lung by transcriptional profiling. Am J Respir Cell Mol Biol, 29, 172–9
   PubMed Web of Science ®Google Scholar
• Terry CF, Loukaci V, Green FR. (2000). Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem, 275, 18138–44
   PubMed Web of Science ®Google Scholar
• Travis LB, Gospodarowicz M, Curtis RE, et al. (2002). Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst, 94, 182–92
   PubMed Web of Science ®Google Scholar
• Trikha M, Corringham R, Klein B, Rossi JF. (2003). Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res, 9, 4653–65
   PubMed Web of Science ®Google Scholar
• van den Borst B, Souren NY, Gielen M, et al. (2011). Association between the IL6-174G/C SNP and maximally attained lung function. Thorax, 66, 179; author reply 179–80
   PubMed Web of Science ®Google Scholar
• Vickers MA, Green FR, Terry C, et al. (2002). Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res, 53, 1029–34
   PubMed Web of Science ®Google Scholar
• Wang Y, Niu XL, Qu Y, et al. (2010). Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett, 295, 110–23
   PubMed Web of Science ®Google Scholar
• Wani MA, Jan FA, Khan NA, et al. (2014). Cancer trends in Kashmir; common types, site incidence and demographic profiles: National Cancer Registry 2000-2012. Ind J Cancer, 51, 133–7
   PubMed Web of Science ®Google Scholar
• White ES, Strom SR, Wys NL, Arenberg DA. (2001). Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J Immunol, 166, 7549–55
   PubMed Web of Science ®Google Scholar
• Wu CW, Wang SR, Chao MF, et al. (1996). Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol, 91, 1417–22
   PubMed Web of Science ®Google Scholar
• Wypasek E, Undas A, Sniezek-Maciejewska M, et al. (2010). The increased plasma C-reactive protein and interleukin-6 levels in patients undergoing coronary artery bypass grafting surgery are associated with the interleukin-6-174G > C gene polymorphism. Ann Clin Biochem, 47, 343–9
   PubMed Web of Science ®Google Scholar
• Zhai R, Liu G, Yang C, et al. (2001). The G to C polymorphism at -174 of the interleukin-6 gene is rare in a Southern Chinese population. Pharmacogenetics, 11, 699–701
   PubMedGoogle Scholar
• Zhang GJ, Adachi I. (1999). Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res, 19, 1427–32
   PubMed Web of Science ®Google Scholar